Business Wire

C-LECTA

Share
c-LEcta Grows Significantly in Fiscal Year 2019, Strong Start In 2020

c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, successfully concludes 2019 and looks confidently to 2020 after a strong first quarter. The successful development of both the product business and the development partnerships resulted in a 114% increase in revenues in 2019 compared to the previous year to currently EUR 9.1 million (2018: EUR 4.2 million). Total revenues including inventory increases of finished goods and own work capitalized amounted to EUR 9.6 million (2018: EUR 4.5 million).

The company thus again grew significantly in 2019 and even exceeded its already ambitious plans. Earnings before interest, taxes, depreciation and amortization (EBITDA) also developed better than planned, slightly above break-even at EUR 0.2 million. In the previous year, the strategic realignment to concentrate on the product business had temporarily burdened EBITDA. The strong development of the product business was also the reason for the particularly good results for the full year 2019. c-LEcta had driven forward the development and distribution of its own products in particular as of recently. This strategy clearly paid off already in 2019 with product revenues growing by 181%. The existing project business in strategic partnerships also grew by 3%.

“The positive development of EBITDA in particular demonstrates the sustainability of c-LEcta’s business model. Currently, however, the strategic focus clearly remains on the further growth of the company and the investments necessary to achieve this,” said Marc Struhalla, CEO and co-founder of c-LEcta. “We are proud of last year’s revenue growth. 114% growth in one year shows us that the strategic changes of the last two years were right. This is already evident in the current year as well. We got off to a good start in 2020 thanks to the product business that has now been prioritized, and are therefore well on track for the year as a whole,” added CFO Thomas Pfaadt.

The number of employees increased further in 2019. In total, c-LEcta had 76 employees as of December 31, 2019. In the course of the year 2020, nine new employees have been hired so far. Thus c-LEcta once again proves its attractiveness as an employer and its ability to attract very good employees even in a tight job market. This will enable the company to continue to drive its current projects for development and distribution of its own products in the future.

These products are aimed at customers in both the pharmaceutical and food industries. c-LEcta is well positioned in both markets and therefore has a solid basis for further growth, especially in the current economic situation. This includes the product DENARASE, for example that is required in the production of vaccines in order to free the finished products from DNA residues from the production process. The increased demand for DENARASE in the first quarter of 2020, among other developments, has resulted in solid growth momentum in the first months of the current year.

c-LEcta again expects to expand its own product portfolio in fiscal year 2020. This includes a new enzyme product for the food sector. In the pharmaceutical sector, the introduction of an ELISA kit in the first half of 2020 will be aimed at proving the residue-free removal of DENARASE from the final product.

“Our product pipeline remains well filled. This is reflected in the product launches planned for 2020. But in the medium and long term as well, we are working on a number of promising products that each have global sales markets. In doing so, we are using our positioning with currently two primary target markets and the two segments of product business and partnerships to optimally exploit our technological platform,” commented Marc Struhalla.

Based on the good results in 2019 and the current business situation, management expects further sales growth in 2020 beyond the results that were achieved in the previous year.

About c-LEcta

c-LEcta is a world-leading biotechnology company with a focus on enzyme engineering and application in regulated markets like the food and pharma industries. The company is based in Leipzig, Germany, and has established itself as a leading player in the realization of high-value biotech products, either in the form of in-house developments or in close cooperation with industry. The company currently employs more than 80 people.

c-LEcta delivers cost-efficient and sustainable production processes which open new markets and allow for better penetration of existing markets. The company is characterized by fast and efficient development of best-in-class biotech solutions and a rapid and successful market introduction and commercialization of the resulting products. This enables c-LEcta to leverage the unique potential of its core technologies. c-LEcta has a proven track record of more than ten successfully commercialized high-value industrial biotech products.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting samarbejder med Mercurial Minds om at forbedre mulighederne inden for digital transformation4.7.2025 01:10:00 CEST | Pressemeddelelse

Andersen Consulting udvider sit udbud af teknologidrevne løsninger med tilføjelsen af samarbejdsfirmaet Mercurial Minds (M.M.), et konsulentfirma inden for digital transformation, AI og IT med base i Pakistan. M.M. blev grundlagt i 2013 og tilbyder en række tjenester, der er designet til at hjælpe organisationer med at udvikle sig og skalere, herunder i forbindelse med deres digitale transformationsstrategi, AI-tjenester, it-rådgivning og udvikling af robuste mobil- og webbrugeroplevelser. Firmaet leverer end-to-end-løsninger – udformning af datadrevne køreplaner, udvikling af intelligent automatisering og levering af sikre mobil- og weboplevelser, der kan skaleres – skræddersyet til virksomheder, der ønsker at forbedre sine forbindelsesmulighederne og opnå indsigter i realtid. M.M. betjener en bred vifte af brancher med fokus på finans, telekommunikation og andre dataintensive sektorer. "Dette samarbejde er en katalysator," siger Nabeel Saiyer, administrerende direktør for M.M. "Vores

Global Tourism Surging Ahead of Economic Growth, With Visits to Hit 30 Billion by 20344.7.2025 01:00:00 CEST | Press release

The World Economic Forum report, in collaboration with Kearney and the Ministry of Tourism Saudi Arabia, predicts a significant uptick in tourist trips across the globeThe tourism sector will contribute $16 trillion to global GDP (more than 11% of the global economy) by 2034, according to World Travel & Tourism Council estimates (WTTC)India and China will be responsible for more than 25% of all outbound travel by 2030 The World Economic Forum has today published a new report forecasting that the travel and tourism industry is projected to serve 30 billion tourist trips by 2034. Travel and Tourism at a Turning Point: Principles for Transformative Growth, produced in collaboration with Kearney and the Ministry of Tourism Saudi Arabia, reveals a projected $16 trillion contribution to global GDP by the same year—representing more than 11% of the total world economy, according to World Travel & Tourism Council estimates. The report also found that the sector is expanding 1.5 times faster th

The 2025-2026 World Branding Awards Animalis Edition Honouring Leading Pet and Animal Brands Globally3.7.2025 21:00:00 CEST | Press release

The 2025-2026 World Branding Awards Animalis Edition marked its fifth instalment, bringing together leading pet and animal brands from all around the world. These brands were celebrated for their outstanding achievements, earning recognition as National, Regional, and Global Winners. The awards ceremony, held at Vienna's prestigious Hofburg Palace, welcomed winners across diverse categories, including pet food, retail, wellness, pet exhibitions, and aquatic products. Mounia Berrada-Gouzi expertly hosted the evening, which culminated in a grand celebration of brand excellence. “The Animalis Edition of the World Branding Awards recognises brands that have achieved the highest distinction—genuine recognition in the hearts and minds of consumers. Tonight, we honour those whose names resonate globally, whose values inspire loyalty, and whose presence defines excellence in the pet and animal industry,” said Richard Rowles, Chairman of the World Branding Forum. Out of over 950 brands nominate

Venture Global Announces 20-Year Sales and Purchase Agreement with PETRONAS3.7.2025 14:59:00 CEST | Press release

Today, Venture Global, Inc. (NYSE: VG) announced the execution of a new 20-year Sales and Purchase Agreement (SPA) with PETRONAS LNG Ltd. (PLL), a subsidiary of the Malaysian state-owned oil and gas company, PETRONAS. Under the terms of the SPA, PETRONAS will purchase 1 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from Venture Global’s third facility, CP2 LNG, for 20 years. This builds upon Venture Global’s existing agreement with PETRONAS for 1 MTPA of LNG supply from Plaquemines LNG. PETRONAS, a world-class partner in the LNG industry, joins other CP2 LNG customers in Europe, Asia and the rest of the world in a strategically important project to global energy supply and security. To date, approximately 10.75 MTPA of the 14.4 MTPA nameplate capacity for CP2 Phase One has been sold. About Venture Global Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets ac

Frost & Sullivan Recognizes Novotech as 2025 Global Biotech CRO Company of the Year3.7.2025 14:05:00 CEST | Press release

In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost & Sullivan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703950144/en/ Novotech Wins Global CRO Award Novotech is a globally recognized full-service clinical CRO and scientific advisory firm, trusted by biotech and small- to mid-sized pharmaceutical companies to advance their drug development programs at every phase. With a global footprint spanning Asia-Pacific, North America, and Europe, Novotech supports over 5,000 clinical trial sites and a distributed team of experts delivering seamless, end-to-end solutions across geographies. “Novotech is redefining biotech-focused clinical research through AI-driven innovation, global expansion, and a client-embedded partnership model. With a clear vision to be the CRO of choice for

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye